Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 55,694 shares at $54.98 ($3.1M) on 2022-02-22, disclosed to the SEC on 2022-02-23.
Open-market sale of $3.1M ITCI by Chairman, President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.98 | 12,667 | $696K | 22.6% |
| 2 | $54.98 | 12,667 | $696K | 22.6% |
| 3 | $55.73 | 15,180 | $846K | 27.4% |
| 4 | $55.73 | 15,180 | $846K | 27.4% |
| Total | $55.39 avg | 55,694 | $3.1M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |